Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Juan-Pablo Mas
AddedMar 31, 2024
UpdatedMay 31, 2026
Juan-Pablo Mas

Juan-Pablo Mas

Board Member, Onc.AI

CrunchbaseLinkedIn

Juan-Pablo Mas's Career

Onc.AI
Onc.AI

San Carlos, CA, US

Board Member· Board
Presidio Medical
Presidio Medical

South San Francisco, CA, US

Board Member· Board
Setpoint Medical
Setpoint Medical

Valencia, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Juan-Pablo Mas's Career

Onc.AI
Onc.AI
Series A$31M302020San Carlos, CA, US
Board Member· Board

Leadership at Onc.AI

Julie HambletonJulie HambletonBoard Member
Jonathan FlemingJonathan FlemingBoard Member
Salmaan AhmedSalmaan AhmedCo-Founder
Emir SandhuEmir SandhuBoard Member
Akshay NanduriAkshay NanduriCo-Founder
David Diaz-CasariegoDavid Diaz-CasariegoBoard Member

Similar to Onc.AI

Precision Health AIPrecision Health AINew York City, NY, USHealthcare, Oncologyest. 2016Precision Health AINew York City, NY, US · est. 2016

Precision Health AI: Leveraging AI for oncology, enhancing outcomes and value-based care.

Series A · $20M30
GenomOncologyGenomOncologyCleveland, OH, USHealthcare, Softwareest. 2012GenomOncologyCleveland, OH, US · est. 2012

GenomOncology: Transforming data into actionable insights for improved cancer care.

Pre-Seed · $2.9M62
OncoPrecisionOncoPrecisionNew York City, NY, USCancer Treatmentest. 2020OncoPrecisionNew York City, NY, US · est. 2020

Developing advanced tech for personalized cancer treatment and aiding in transformative therapy creation.

Seed · $4.2M37
OncoLensOncoLensAtlanta, GA, USTumor Board Softwareest. 2016OncoLensAtlanta, GA, US · est. 2016

OncoLens: Streamlining cancer case reporting with our efficient tumor board software solution.

Series A · $11.8M39
Presidio Medical
Presidio Medical
Series C$102M592017South San Francisco, CA, US
Board Member· Board

Leadership at Presidio Medical

Kenneth WuKenneth WuFounder
Michael OnuscheckMichael OnuscheckBoard Member
Kenneth WuKenneth WuBoard Member
Setpoint Medical
Setpoint Medical
Series D$344M1752007Valencia, CA, US
Board Member· Board

Leadership at Setpoint Medical

Kevin TraceyKevin TraceyCo-Founder
Allan WillAllan WillBoard Member
Jim BroderickJim BroderickCo-Founder
Murthy SimhambhatlaMurthy SimhambhatlaCEO
Josh MakowerJosh MakowerBoard Member
Hank PlainHank PlainBoard Member

Juan-Pablo Mas's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Juan-Pablo Mas

Imran EbaImran EbaBoard Member · Alpheus MedicalJohn EltonJohn EltonBoard Member · Rapid RoboticsAjay AgarwalAjay AgarwalBoard Member · ClockwiseMike VernalMike VernalGeneral Partner · Conviction PartnersJohn HoJohn HoBoard Member · SolchromaJeff BocanJeff BocanBoard Member · Givelist